Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)

Keros Therapeutics filings provide 7 years of Cash from Financing Activities readings, the most recent being -$378.6 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 601.21% to -$378.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$378.5 million, a 196.59% decrease, with the full-year FY2025 number at -$378.5 million, down 196.59% from a year prior.
  • Cash from Financing Activities hit -$378.6 million in Q4 2025 for Keros Therapeutics, down from $140000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $156.8 million in Q1 2024 to a low of -$378.6 million in Q4 2025.
  • Median Cash from Financing Activities over the past 5 years was $2.6 million (2023), compared with a mean of $17.1 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 138708.57% in 2022 and later plummeted 601.21% in 2025.
  • Keros Therapeutics' Cash from Financing Activities stood at $28.4 million in 2021, then surged by 116.13% to $61.4 million in 2022, then rose by 12.76% to $69.3 million in 2023, then rose by 9.08% to $75.5 million in 2024, then plummeted by 601.21% to -$378.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$378.6 million (Q4 2025), $140000.0 (Q3 2025), and $17000.0 (Q2 2025) per Business Quant data.